- Home
- SF vs PCVX Comparison
SF vs PCVX Comparison
Compare SF & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SF | PCVX |
|---|---|---|
| Founded | 1890 | 2013 |
| Country | United States | United States |
| Employees | 9000 | 507 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 7.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SF | PCVX |
|---|---|---|
| Price | $72.49 | $47.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $90.33 | $88.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.58 | N/A |
| Revenue Next Year | $8.03 | N/A |
| P/E Ratio | $20.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.31 | $29.10 |
| 52 Week High | $134.74 | $65.00 |
Technical Indicators
Market Signals| Indicator | SF | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.26 | 28.03 |
| Support Level | $69.31 | $42.30 |
| Resistance Level | $74.07 | $49.46 |
| Average True Range (ATR) | 1.92 | 2.71 |
| MACD | -0.29 | -0.87 |
| Stochastic Oscillator | 11.99 | 6.56 |
Price Performance
Historical ComparisonAbout SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.